# HIV Viral Suppression With Unintentional Lenacapavir Monotherapy in Adherence-Challenged Patients: A Case Series

## TL;DR

This case series shows that lenacapavir, an HIV drug, can suppress the virus in patients who unintentionally take it alone, even with adherence issues.

## Contribution

Demonstrates lenacapavir monotherapy's effectiveness in maintaining HIV suppression in patients with adherence challenges.

## Key findings

- Four patients maintained HIV suppression with unintentional lenacapavir monotherapy for 9–38 weeks.
- The results suggest lenacapavir may be effective for adherence-challenged populations.
- This highlights the drug's potential for use in patients with severe mental illness and homelessness.

## Abstract

Lenacapavir, a long-acting human immunodeficiency virus (HIV) capsid inhibitor, is thought to have a low resistance barrier based on current, limited data. We describe 4 patients experiencing homelessness with severe mental illness who maintained HIV suppression (<30 copies/mL) despite unintentional receipt of lenacapavir monotherapy for 9–38 weeks, highlighting its potential among adherence-challenged populations.